Ancestral HLA-II origin review 2025 — H5 conceptual framing anchor

One-paragraph summary

Review proposing that the three ancestral HLA class II haplotypes — DR2-DQ6, DR4-DQ8, DR3-DQ2 — confer central susceptibility to autoimmune diseases including Long COVID, ME/CFS, and post-vaccination syndromes. The evolutionary thesis: these haplotypes were selected in historical contexts of high infectious pressure because of strong T-cell responses against pathogens; the same antigenic promiscuity in modern environments is associated with immune hyperreactivity → tolerance breakdown → autoimmunity. Pro-inflammatory cytokine release (IFN-γ etc.) is the mechanism. Modifiers include chronic infections, immunotherapies, vaccination, obesity, and chronic physical stressors. Discusses therapeutic implications of HLA-II profiling in clinical practice. This is the conceptual framing anchor for the H5 framework: it justifies why HLA-DQ2/DQ8 (within DR3-DQ2 and DR4-DQ8 haplotypes) is in the H5 module and provides the evolutionary-biology framing that H5 currently lacks.

Claims as triples

• HLA_DR2_DQ6 — increases_risk → autoimmune_disease [evidence: review consolidation of multi-condition GWAS; confidence: established]
• HLA_DR4_DQ8 — increases_risk → autoimmune_disease [evidence: review consolidation; confidence: established]
• HLA_DR3_DQ2 — increases_risk → autoimmune_disease [evidence: review consolidation; confidence: established]
• ancestral_HLA_II — increases_risk → me_cfs [evidence: review framework; confidence: emerging]
• ancestral_HLA_II — increases_risk → post_covid_syndrome [evidence: review framework; confidence: emerging]
• ancestral_HLA_II — increases_risk → post_vaccination_syndrome [evidence: review framework; confidence: emerging-but-evidence-limited (per authors)]
• HLA_immune_hyperreactivity — drives → tolerance_breakdown [evidence: framework consolidation; confidence: emerging]

Methods note

Narrative review of HLA class II haplotype association studies and evolutionary biology. The evolutionary framing is novel and provides conceptual structure; the underlying gene-disease associations are well-established.

Limitations

• Narrative review, not new primary data
• Evolutionary framing is theoretical
• The authors explicitly note that evidence for ancestral-HLA-II involvement in post-vaccination syndromes is limited
• FM extension is project-driven; no explicit FM discussion in the paper
• Doesn't address whether FM-specific HLA susceptibility alleles differ from celiac/T1DM-pattern (HLA-DQ2/DQ8 in DR3-DQ2 and DR4-DQ8 haplotypes) — leaves the FM-specific genetic architecture an open empirical question

Open questions raised

• Q-Gen-16 (new): Are the three ancestral HLA-II haplotypes (DR2-DQ6, DR4-DQ8, DR3-DQ2) enriched in FM-IgG-positive vs FM-IgG-negative patients? This extends Q-Gen-1 (HLA-DQ2/DQ8 only) to the broader DR-DQ haplotype framework.
• Q-Gen-17 (new): Does FM exhibit the same "modern environment hyperreactivity" pattern (chronic infections + immunotherapies + obesity + chronic stress as amplifiers) the paper proposes for autoimmune diseases generally? Most of these modifiers are already in the FM trigger ontology — but the H5 framework now provides explicit upstream-genetic-substrate context for them.

Triangulation notes

• H5 conceptual framing: provides the evolutionary-biology rationale for why HLA-DQ2/DQ8 carriers are predicted to enrich in autoimmune-tolerance-failure FM phenotypes. The framework explains the population-genetic persistence of these alleles despite autoimmunity risk.
• Extends Georgopoulos 2025: that paper showed ME/CFS-susceptibility-allele weak binding to viral antigens (pathogen-antigen-escape framing); this paper supplies the converse interpretation (susceptibility alleles bind broadly → hyperreactivity → tolerance breakdown). The two framings are complementary — weak antigen-clearance + broad reactivity may both characterize the same allele set.
• Connects to project trigger ontology: chronic infections + immunotherapies + obesity + chronic stress are existing FM triggers. This review reframes them as modifiers of an underlying HLA-II-driven hyperreactivity rather than independent triggers — providing the upstream-genetic-substrate that H5 has been positing.
• Compatible with Kerrebijn 2025 subset-mechanism-dilution: the population-level FM GWAS not finding immune-tissue heritability enrichment is consistent with the HLA susceptibility being a subset phenomenon at biobank scale — ancestral HLA-II haplotypes are common (~half the population by carriage) but only the symptomatic-autoimmune subset is captured by the FM ICD-code ascertainment.

Bridges

• H5 conceptual framing: provides the conceptual anchor that the H5 hypothesis was previously missing. The H5 framework's evolutionary justification now has a citation.

Ontology additions needed

• Consider adding HLA_DR2_DQ6, HLA_DR4_DQ8, HLA_DR3_DQ2 as new haplotype entities (broader than HLA_DQ2_DQ8)
• Consider adding ancestral_HLA_II as composite-process entity
• Consider adding post_vaccination_syndrome as comorbidity entity (per author noting evidence-limited)
• Consider adding HLA_immune_hyperreactivity as mechanism entity

Chain-map update

• H5 conceptual layer: H5 framework gains the evolutionary-biology context. The HLA-DQ2/DQ8 arm in the H5 module is now framed as one specific instance of a broader ancestral-HLA-II haplotype risk pattern.
• Cross-condition framework expansion: the H5 framework can now plausibly extend beyond celiac+T1DM to include the broader ancestral-HLA-II-associated autoimmune-disease spectrum (which includes RA, SLE, MS, T1DM, celiac, autoimmune thyroid).

Confidence-tier framing

• Ancestral HLA-II haplotypes increase autoimmune disease risk: established
• Same haplotypes increase ME/CFS / post-COVID syndrome risk: emerging (review consolidation)
• HLA-II-driven hyperreactivity as mechanism of tolerance breakdown: emerging
• Same framework operative in FM: bridging (project-driven extrapolation)
• Evolutionary framing of HLA-II persistence: theoretical (review hypothesis)